Wize Pharma Stock

Wize Pharma EV/EBIT

Delisted·Jan 10, 2019

The EV/EBIT (Enterprise Value to EBIT) of Wize Pharma (WIZP) as of Aug 4, 2026 is -181.23. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -139.61 — a change of 29.81% (lower).

EV/EBIT

-181.23

YoY

29.81%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Wize Pharma is 2026 -181.23 . EV/EBIT (Enterprise Value to EBIT) of Wize Pharma was 2025 -139.61 . It decreases by 29.81% lower compared to the previous year.

The Wize Pharma EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2017
-11.93 base
Jan 1, 2018
-5.90 base
Jan 1, 2019
-6.76 base
Jan 1, 2020
0.00 base
Jan 1, 2021 (e)
0.00 base
Jan 1, 2022 (e)
0.00 base
Jan 1, 2023 (e)
0.00 base
Jan 1, 2024 (e)
0.00 base
YEARPRICE-TO-EBIT
2024 est -
2023 est -
2022 est -
2021 est -
2020 -
2019 -6.76
2018 -5.90
2017 -11.93
2016 -22.12
2015 -7.42
2014 74.50
2013 -836.40
2012 -4,539.50
2011 -78,820.86
2010 -870,665.04
2009 -402,464.78
2008 -37,619.70
2007 -571,819.45
2006 -
Access this data via the Eulerpool API
Get Free API Key

Wize Pharma Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Wize Pharma's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Wize Pharma's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Wize Pharma's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Wize Pharma grows earnings faster than its peers.

Wize Pharma Stock analysis

What does Wize Pharma do? Wize Pharma Inc. is a leading biopharmaceutical company specializing in the development and marketing of innovative products for the treatment of eye diseases. The company was founded in 1997 and is headquartered in Herzliya Pituach, Israel. It focuses on the research, development, manufacturing, and marketing of eye disease treatments. The company aims to become a leading brand in the field of eye health and offers high-quality services in eye care. Wize Pharma Inc. operates different divisions, with its main divisions being the development and marketing of eye therapeutics, including LO2A and LO2B. LO2A is an innovative therapy for dry eye, while LO2B is an intraoperative formulation used in glaucoma surgery. The company's products provide effective and sustainable solutions for the treatment of eye diseases. Wize Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Wize Pharma stock

EV/EBIT (Enterprise Value to EBIT) of Wize Pharma is -181.23 in 2026.

EV/EBIT (Enterprise Value to EBIT) of Wize Pharma changed from -139.61 to -181.23, representing a 29.81% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Wize Pharma since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Wize Pharma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API
Get Free API Key

Valuation — Wize Pharma

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueEV/EBITForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Wize Pharma